imatinib mesylate · Shorla Oncology · NDA 219097
Imkeldi
Earliest generic entry, as listed
27 Apr 2040
Blocked by patent: US 11957681.
Listed patents · 1 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11957681 | drug product · sets the listed date | 27 Apr 2040 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 219097 · 001 · RLD | solution, oral | EQ 80MG BASE/ML | 27 Apr 2040 |